Strategies for improving long-term survival in peritoneal dialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 6, 2010, Pages 1123-1131

  Kendrick, Jessica ^a   Teitelbaum, Isaac ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; MORBIDITY; MORTALITY; PERITONEAL DIALYSIS; PREVALENCE; REVIEW; SURVIVAL; UNITED STATES; ARTIFICIAL MEMBRANE; CARDIOVASCULAR DISEASES; COMMUNICABLE DISEASES; COMPLICATION; EQUIPMENT DESIGN; INFECTION CONTROL; KIDNEY; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; SURVIVOR; TIME; TREATMENT OUTCOME;

ARTIFICIAL MEMBRANE;

CARDIOVASCULAR DISEASES; COMMUNICABLE DISEASES; EQUIPMENT DESIGN; HUMANS; INFECTION CONTROL; KIDNEY; KIDNEY FAILURE, CHRONIC; MEMBRANES, ARTIFICIAL; PERITONEAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953313703     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04300709     Document Type: Review

References (77)

1. U.S. Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2008
2. Mujais S, Story K: Peritoneal dialysis in the US: Evaluation of outcomes in contemporary cohorts. Kidney Int Suppl 103: S21-S26, 2006
3. Buraczynska M, Ksiazek P, Zukowski P, Benedyk-Lorens E, Orlowska-Kowalik G: Complement factor H gene polymorphism and risk of cardiovascular disease in end stage renal disease patients. Clin Immunol 132: 285-290, 2009
4. Tentori F, Blayney M, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPS). Am J Kidney Dis 52: 519-530, 2008
5. Foley R, Parfrey P, Harnett J, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61, 1996 (Pubitemid 26231466)
6. Shlipak M, Fried L, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B: Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA 293: 1737-1745, 2005
7. Stenvinkel P, Heimburger O, Lindholm B: Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. Nephrol Dial Transplant 19: 2181-2183, 2004
8. Kendrick J, Chonchol M: Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 4: 672-681, 2008
9. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 7: 198-207, 1996
10. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13: 1307-1320, 2002 (Pubitemid 34441412)
11. Lo WK, Ho YW, Li CS, Wong KS, Chan TM, Yu AW, Ng FS, Cheng IK: Effect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study. Kidney Int 64: 649-656, 2003
12. Bargman JM, Thorpe KE, Churchill DN: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 12: 2158-2162, 2001
13. Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT: The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 241: 1293-1302, 2003
14. Liao CT, Chen YM, Shiao CC, Hu FC, Huang JW, Kao TW, Chuang HF, Hung KY, Wu KD, Tsai TJ: Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. Nephrol Dial Transplant 24: 2909-2914, 2009
15. Marron B, Remon C, Perez-Fontan M, Quiros P, Ortiz A: Benefits of preserving residual renal function in peritoneal dialysis. Kidney Int Suppl 108: S42-S51, 2008
16. Haag-Weber M: The impact of residual renal function on survival. Nephrol Dial Transplant 23: 2123-2126, 2008
17. Han SH, Lee SC, Ahn SV, Lee JE, Kim DK, Lee TH, Moon SJ, Kim BS, Kang SW, Choi KH, Lee HY, Han DS: Reduced residual renal function is a risk of peritonitis in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 22: 2653-2658, 2007
18. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57: 601-606, 2000
19. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354: 359-364, 1999
20. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
21. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, Hulbert-Shearon T, Jones CA, Bloembergen WE: Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 11: 556-564, 2000 (Pubitemid 30115086)
22. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC: Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 139: 105-112, 2003
23. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H: Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 43: 1056-1064, 2004 (Pubitemid 38691501)
24. Fang W, Oreopoulos DG, Bargman JM: Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 23: 3704-3710, 2008
25. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47[Suppl 3]: S1-S145, 2006
26. Kim SG, Kim S, Hwang YH, Kim K, Oh JE, Chung W, Oh KH, Kim HJ, Ahn C: Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study). Perit Dial Int 28[Suppl 3]: S117-S122, 2008
27. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J: The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66: 408-418, 2004
28. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM: Randomized controlled study of biocompatible peritoneal dialysis solutions: Effect on residual renal function. Kidney Int 73: 200-206, 2008
29. Moranne O, Willoteaux S, Pagniez D, Dequiedt P, Boulanger E: Effect of iodinated contrast agents on residual renal function in PD patients. Nephrol Dial Transplant 21: 1040-1045, 2006
30. Dittrich E, Puttinger H, Schillinger M, Lang I, Stefenelli T, Horl WH, Vychytil A: Effect of radio contrast media on residual renal function in peritoneal dialysis patients - A prospective study. Nephrol Dial Transplant 21: 1334-1339, 2006
31. Kshirsagar AV, Poole C, Mottl A, Shoham D, Franceschini N, Tudor G, Agrawal M, Denu-Ciocca C, Magnus-Ohman E, Finn WF: N-acetylcysteine for the prevention of radiocontrast induced nephropathy: A meta-analysis of prospective controlled trials. J Am Soc Nephrol 15: 761-769, 2004
32. Medcalf JF, Harris KP, Walls J: Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 59: 1128-1133, 2001
33. Shemin D, Maaz D, St Pierre D, Kahn SI, Chazan JA: Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis 34: 14-20, 1999 (Pubitemid 29318790)
34. Baker RJ, Senior H, Clemenger M, Brown EA: Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 41: 670-675, 2003
35. Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, Kuijper EJ, Li PK, Lye WC, Mujais S, Paterson DL, Fontan MP, Ramos A, Schaefer F, Uttley L: Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 25: 107-131, 2005
36. Hiroshige K, Yuu K, Soejima M, Takasugi M, Kuroiwa A: Rapid decline of residual renal function in patients on automated peritoneal dialysis. Perit Dial Int 16: 307-315, 1996 (Pubitemid 26202709)
37. Hufnagel G, Michel C, Queffeulou G, Skhiri H, Damieri H, Mignon F: The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 14: 1224-1228, 1999
38. Badve SB, Hawley CM, McDonald SP, Mudge DW, Rosman JB, Brown FG, Johnson DW: Automated and continuous ambulatory peritoneal dialysis have similar outcomes. Kidney Int 73: 480-488, 2008
39. Mehrotra R, Chiu YW, Kalantar-Zadeh K, Vonesh E: The outcomes of continuous ambulatory and automated peritoneal dialysis are similar. Kidney Int 76: 97-107, 2009
40. Flessner MF: The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol 288: F433-F442, 2005
41. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, Ikeda K, Horiuchi S: Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant 14: 1541-1549, 1999
42. Davies SJ, Phillips L, Griffiths AM, Russell LH, Naish PF, Russell GI: What really happens to people on long-term peritoneal dialysis? Kidney Int 54: 2207-2217, 1998
43. Goffin E: Peritoneal membrane structural and functional changes during peritoneal dialysis. Semin Dial 21: 258-265, 2008
44. Flessner MF: The effect of fibrosis on peritoneal transport. Contrib Nephrol 150: 174-180, 2006
45. Flessner MF, Credit K, Henderson K, Vanpelt HM, Potter R, He Z, Henegar J, Robert B: Peritoneal changes after exposure to sterile solutions by catheter. J Am Soc Nephrol 18: 2294-2302, 2007
46. Rumpsfeld M, McDonald SP, Johnson DW: Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. J Am Soc Nephrol 17: 271-278, 2006
47. Chung SH, Chu WS, Lee HA, Kim YH, Lee IS, Lindholm B, Lee HB: Peritoneal transport characteristics, comorbid diseases and survival in CAPD patients. Perit Dial Int 20: 541-547, 2000
48. Wang T, Heimburger O, Waniewski J, Bergstrom J, Lindholm B: Increased peritoneal permeability is associated with decreased fluid and small-solute removal and higher mortality in CAPD patients. Nephrol Dial Transplant 13: 1242-1249, 1998
49. Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG: Meta-analysis: Peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 17: 2591-2598, 2006
50. Brown EA, Davies SJ, Rutherford P, Meeus F, Borras M, Riegal W, Divino-Filho JC, Vonesh E, van Bree M: Survival of functionally anuric patients on automated peritoneal dialysis: The European APD Outcome Study. J Am Soc Nephrol 14: 2948-2957, 2003
51. de Alvaro F, Castro MJ, Dapena F, Bajo MA, Fernandez-Reyes MJ, Romero JR, Jimenez C, Miranda B, Selgas R: Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. Adv Perit Dial 9: 56-61, 1993
52. Zhe X, Tian X, Cheng L, Wang T: Effects of peritoneal resting on peritoneal fluid transport kinetics. Perit Dial Int 27: 575-579, 2007 (Pubitemid 351176022)
53. Kim YL, Kim SH, Kim JH, Kim SJ, Kim CD, Cho DK, Kim YJ, Moberly JB: Effects of peritoneal rest on peritoneal transport and peritoneal membrane thickening in continuous ambulatory peritoneal dialysis rats. Perit Dial Int 19[Suppl 2]: S384-S387, 1999
54. Davies SJ, Phillips L, Naish PF, Russell GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 12: 1046-1051, 2001 (Pubitemid 32378346)
55. Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-Carmona A, Vychytil A, Macnamara E, Ekstrand A, Tranaeus A, Filho JC: Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 67: 1609-1615, 2005
56. Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim YL, Kim DJ, Kim YS, Kim MJ, Shin SK: Changing prescribing practice in CAPD patients in Korea: Increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 21: 2893-2899, 2006
57. Duman S, Wieczorowska-Tobis K, Styszynski A, Kwiatkowska B, Breborowicz A, Oreopoulos DG: Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum. Adv Perit Dial 20: 31-36, 2004
58. Marchesi C, Paradis P, Schiffrin EL: Role of the reninangiotensin system in vascular inflammation. Trends Pharmacol Sci 29: 367-374, 2008
59. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB: Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 25: 38-47, 2005 (Pubitemid 40378496)
60. Duman S, Gunal AI, Sen S, Asci G, Ozkahya M, Terzioglu E, Akcicek F, Atabay G: Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 21: 219-224, 2001
61. Kolesnyk I, Dekker FW, Noordzij M, le Cessie S, Struijk DG, Krediet RT: Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients. Perit Dial Int 27: 446-453, 2007 (Pubitemid 47207733)
62. Kolesnyk I, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT: A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 24: 272-277, 2009
63. Nishimura H, Ito Y, Mizuno M, Tanaka A, Morita Y, Maruyama S, Yuzawa Y, Matsuo S: Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. Am J Physiol Renal Physiol 294: F1084-F1093, 2008
64. Fried LF, Bernardini J, Johnston JR, Piraino B: Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 7: 2176-2182, 1996 (Pubitemid 27468247)
65. Mujais S: Microbiology and outcomes of peritonitis in North America. Kidney Int Suppl 103: S55-S62, 2006
66. Gadallah M, Ramdeen G, Mignone J, Patel D, Mitchell L, Tatro S: Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters. Am J Kidney Dis 36: 1014-1019, 2000
67. Wikdahl A, Engman U, Stegmayr B, Sorenssen J: One-dose cefuroxime i.v. and i.p. reduces microbial growth in PD patients after catheter insertion. Nephrol Dial Transplant 12: 157-160, 1997
68. Hall G, Bogan A, Dreis S, Duffy A, Greene S, Kelley K, Lizak H, Nabut J, Schinker V, Schwartz N: New directions in peritoneal dialysis patient training. Nephrol Nurs J 31: 149-154, 159-163, 2004
69. Bernardini J, Bender F, Florio T, Sloand J, Palmmontalbano L, Fried L, Piraino B: Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol 16: 539-545, 2005
70. Furkert J, Zeier M, Schwenger V: Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates. Perit Dial Int 28: 637-640, 2008
71. Fusshoeller A, Plail M, Grabensee B, Plum J: Biocompatibility pattern of a bicarbonate/lactate buffered peritoneal dialysis fluid in APD: A prospective, randomized study. Nephrol Dial Transplant 19: 2101-2106, 2004
72. Puig-Kroger A, Pello O, Selgas R, Criado G, Bajo MA, Sanchez-Tomero JA, Alvarez V, del Peso G, Sanchez-Mateos P, Holmes C, Faict D, Lopez-Cabrera M, Madrenas J, Corbi AL: Peritoneal dialysis solutions inhibit the differentiation and maturation of human monocyte-derived dendritic cells: Effect of lactate and glucose degradation products. J Leukoc Biol 73: 482-492, 2003
73. Oo TN, Roberts TL, Collins AJ: A comparison of peritonitis rates from the United States Renal Data System database: CAPD versus continuous cycling peritoneal dialysis patients. Am J Kidney Dis 45: 372-380, 2005
74. Kavanagh D, Prescott GJ, Mactier RA: Peritoneal dialysisassociated peritonitis in Scotland (1999 -2002). Nephrol Dial Transplant 19: 2584-2591, 2004
75. Nessim SJ, Bargman JM, Austin PC, Nisenbaum R, Jassal SV: Predictors of peritonitis in patients on peritoneal dialysis: Results of a large, prospective Canadian database. Clin J Am Soc Nephrol 4: 1195, 2009
76. Yang CY, Chen TW, Lin YP, Lin CC, Ng YY, Yang WC, Chen JY: Determinants of catheter loss following continuous ambulatory peritoneal dialysis peritonitis. Perit Dial Int 28: 361-370, 2008
77. Schaubel DE, Blake PG, Fenton SS: Effect of renal center characteristics on mortality and technique failure on peritoneal dialysis. Kidney Int 60: 1517-1524, 2001